Why Don't Patients With Pain Become Addicted to Morphine?

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

GLASGOW-Pain specialists continually stress the message that clinicians should not fear prescribing adequate doses of opioids for pain patients, since such patients are not at risk of becoming "addicted."

GLASGOW-Pain specialists continually stress the message that cliniciansshould not fear prescribing adequate doses of opioids for painpatients, since such patients are not at risk of becoming "addicted."

Now a study from the University of Glasgow confirms what painspecialists intuitively know: Pain patients do not become psychologicallydependent on drugs because they are taking narcotics to relievetheir pain and for no other reason; drug abusers, on the otherhand, use narcotics strictly for mood alteration or to inducesleep.

The researchers surveyed three groups who were receiving narcotics:cancer pain patients (14 subjects), patients with chronic nonmalignantpain (27 subjects), and drug addicts enrolled in a methadone maintenanceprogram (30 subjects).

The cancer pain patients had been using opioids for a mean of6 months; the chronic pain patients for 2.2 years; and the drugabusers for 13 years. Median daily morphine equivalent doses weremuch higher in the cancer patients (1,320 mg) than in the chronicpain patients (700 mg) or the drug abusers (160 mg).

Patients' drug use and reasons for varying the dose were recordeddaily for a week, then weekly for a month, then once monthly for3 months, via structured questionnaires and semi-structured interviews,Dr. Marie Fallon, of the Division of Palliative Medicine, reportedin a poster session at the 8th World Congress on Pain in Vancouver.

The results showed that pain patients are not psychologicallydependent on strong opioids. "They have a need to use themfor pain, and when that pain isn't there, they basically don'tneed them," Dr. Fallon said.

The cancer pain patients reported taking extra opioids when theirpain was poorly controlled, and the chronic pain patients saidthey took extra doses when pain was more distressing, but, Dr.Fallon said, the drug abusers' use of extra narcotics beyond whatthey were getting in the maintenance program appeared to be basedon drug availability.

Recent Videos
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.